Minodronate.

Animals Bone Density Conservation Agents Diphosphonates / pharmacology Humans Imidazoles / pharmacology Japan Osteoporosis
Bone mineral density Bone quality Farnesyl pyrophosphate synthase Fracture prevention Heterocyclic nitrogen-containing bisphosphonate Hydroxyapatite affinity

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
08 2020
Historique:
received: 26 01 2020
revised: 12 05 2020
accepted: 13 05 2020
pubmed: 19 5 2020
medline: 22 6 2021
entrez: 19 5 2020
Statut: ppublish

Résumé

Minodronate is a heterocyclic nitrogen-containing bisphosphonate with high potency in inhibiting bone resorption, and is developed for clinical use in Japan. Minodronate has very high potency in inhibiting farnesyl pyrophosphate synthase, and shows lower affinity for bone matrix hydroxyapatite at both neutral and acidic pH. As a result, small amount of minodronate is deposited in bone but can exert strong anti-resorptive activity in vivo. In this review on minodronate, we summarize the mechanism of action, physico-chemical properties, effects on bone quality in animals, and effects on bone turnover, bone mineral density and fracture prevention, as well as safety in the treatment of patients with osteoporosis.

Identifiants

DOI: 10.1016/j.bone.2020.115432 PMID: 32422295
pubmed: 32422295
pii: S8756-3282(20)30212-X
doi: 10.1016/j.bone.2020.115432
pii:
doi:

Substances chimiques

Bone Density Conservation Agents 0
Diphosphonates 0
Imidazoles 0
YM 529 127657-42-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115432

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Toshio Matsumoto (T)

Fujii Memorial Institute of Medical Sciences, Tokushima University, Japan. Electronic address: toshio.matsumoto@tokushima-u.ac.jp.

Itsuro Endo (I)

Department of Bioregulatory Sciences, Tokushima University Graduate School of Medical Sciences, Tokushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Minodronate.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents de maintien de la densité osseuse › Minodronate.
questionsmedicales.fr › Composés chimiques organiques › Composés organiques du phosphore › Phosphonates › Diphosphonates › Minodronate.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Minodronate.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Minodronate.
questionsmedicales.fr › Régions géographiques › Iles › Japon › Minodronate.
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Maladies osseuses métaboliques › Ostéoporose › Minodronate.